|
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. |
|
|
Honoraria - AstraZeneca; Novartis; Novartis; Pharmacyclics; Syndax; Trillium Therapeutics |
Consulting or Advisory Role - Acerta Pharma; Genentech; Jazz Pharmaceuticals; Pharmacyclics |
Research Funding - Acerta Pharma (Inst); Pharmacyclics (Inst) |
|
|
Honoraria - Abbvie; Janssen; Roche |
Research Funding - Abbvie (Inst); Gilead Sciences (Inst); Janssen (Inst); Pharmacyclics (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Abbvie; Janssen |
|
|
Honoraria - Abbvie; ArQule; AstraZeneca; BeiGene; Gilead Sciences; Janssen; Juno/Celgene/Bristol-Myers Squibb; Loxo/Lilly |
Consulting or Advisory Role - Abbvie; ArQule; AstraZeneca; BeiGene; Gilead Sciences; Janssen; Juno/Celgene/Bristol-Myers Squibb; Loxo/Lilly |
Research Funding - Abbvie (Inst); Gilead Sciences (Inst); Janssen (Inst); Novartis (Inst); Sunesis Pharmaceuticals (Inst) |
|
|
Consulting or Advisory Role - Abbvie/Genentech; AstraZeneca; Bristol-Myers Squibb/Celgene; Janssen Oncology; lava therapeutics |
Research Funding - Abbvie; AstraZeneca; Bristol-Myers Squibb/Celgene; Janssen Oncology; Roche/Genentech |
Travel, Accommodations, Expenses - Acerta Pharma/AstraZeneca; Roche/Genentech; Roche/Genentech |
|
Asher Alban Akmal Chanan-Khan |
Stock and Other Ownership Interests - Matthew & Asher Inc.; NanoDev Therapeutics |
|
Research Funding - Ascentage Pharma |
Patents, Royalties, Other Intellectual Property - Patent on PSMB9 biomarker |
|
|
Honoraria - AstraZeneca; Janssen |
Consulting or Advisory Role - Abbvie; Acerta Pharma; AstraZeneca; Beigene; Genentech/Roche; Incyte; Janssen Biotech; Loxo; MorphoSys; OncoTracker; Pharmacyclics; Sanofi; TG Therapeutics; Verastem |
Research Funding - Acerta Pharma; TG Therapeutics |
Expert Testimony - Abbvie; Janssen Oncology |
Travel, Accommodations, Expenses - Janssen Oncology; TG Therapeutics |
Other Relationship - Incyte; Janssen Biotech |
|
|
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; Amgen; Aptose Biosciences; Astellas Pharma; Autolus; Bristol-Myers Squibb; Celgene; Eisai; Gilead Sciences; GlaxoSmithKline; Janssen; Johnson & Johnson; Juno Therapeutics; Merck; Pharmacyclics; Vaniam Group; Verastem; Vida Ventures |
Research Funding - Acerta Pharma (Inst); Gilead Sciences (Inst); Kite, a Gilead company (Inst); Pfizer (Inst); Pharmacyclics (Inst); Regeneron (Inst); Sunesis Pharmaceuticals (Inst); TG Therapeutics (Inst) |
|
|
Honoraria - Johnson & Johnson; Pfizer |
Travel, Accommodations, Expenses - Johnson & Johnson |
|
|
Consulting or Advisory Role - Celgene; Janssen; Novartis; Pfizer; Roche; Takeda |
Research Funding - Seagen; Takeda |
Travel, Accommodations, Expenses - Janssen; Novartis; Pfizer; Roche |
|
|
Consulting or Advisory Role - Abbvie (Inst); Acerta Pharma/AstraZeneca (Inst); Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CytomX Therapeutics (Inst); DAVA Pharmaceuticals (Inst); Genentech/Abbvie (Inst); Janssen Biotech (Inst); Juno Therapeutics (Inst); MEI Pharma (Inst); MorphoSys (Inst); Oncotracker (Inst); Pharmacyclics (Inst); Rigel (Inst); Sunesis Pharmaceuticals (Inst); Targeted Oncology (Inst); TG Therapeutics (Inst); Tolero Pharmaceuticals (Inst) |
Research Funding - Abbvie; Acerta Pharma; Bristol-Myers Squibb; Celgene; Genentech; MEI Pharma; Pharmacyclics/Janssen; Sunesis Pharmaceuticals; TG Therapeutics; Tolero Pharmaceuticals |
|
Jose Antonio Garcia Marco |
Consulting or Advisory Role - Abbvie; Janssen |
Speakers' Bureau - Abbvie; Janssen; Roche |
Research Funding - Janssen (Inst) |
|
|
Consulting or Advisory Role - Abbvie/Genentech; Acerta Pharma/AstraZeneca; Adaptive Biotechnologies; Bristol-Myers Squibb/Pfizer; Celgene; Curio/Vaniam Group; DTRM; Johnson & Johnson; Loxo/Lilly; Merck; Pharmacyclics; TG Therapeutics; Verastem |
Research Funding - Abbvie/Genentech; Acerta Pharma/AstraZeneca; Adaptive Biotechnologies; DTRM; Genmab; Johnson & Johnson; LOXO; Nurix; Pharmacyclics; Regeneron; Sunesis Pharmaceuticals; TG Therapeutics |
|
|
Honoraria - Abbvie; Acerta Pharma; Janssen; Roche; Sunesis Pharmaceuticals; Takeda |
Consulting or Advisory Role - Abbvie; Acerta Pharma; AstraZeneca; BMS; Gilead Sciences; Janssen; MEI Pharma; MorphoSys; Roche; Sunesis Pharmaceuticals; Takeda |
Speakers' Bureau - Abbvie; Roche |
Research Funding - Abbvie; Celgene; Janssen; Roche |
|
Travel, Accommodations, Expenses - Abbvie; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; AstraZeneca; Celgene; Gilead Sciences; GlaxoSmithKline; Janssen; Roche |
Consulting or Advisory Role - Abbvie; AstraZeneca; Celgene; Gilead Sciences; GlaxoSmithKline; Janssen; Roche |
Speakers' Bureau - Abbvie; AstraZeneca; Celgene; Gilead Sciences; GlaxoSmithKline; Janssen; Roche |
Research Funding - Abbvie; AstraZeneca; Celgene; Gilead Sciences; GlaxoSmithKline; Janssen; Roche |
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Celgene; Gilead Sciences; GlaxoSmithKline; Janssen; Roche |
|
|
|
Consulting or Advisory Role - Abbvie; Abbvie |
Research Funding - Abbvie/Genentech (Inst) |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
Employment - AstraZeneca; PROMETRIKA |
|
|
|
Stock and Other Ownership Interests - Theravance |
|
|
No Relationships to Disclose |